Cambria Cannabis ETF (TOKE) Dividend History

Company News

• Philip Morris' Q3 Earnings Beat Puts ETFs in Focus

  Look into ETFs with an exposure in PM, as the tobacco company reports robust Q3 earnings.

  Zacks Investment Research

  Featured Companies: DURA FDL IYK PM RDIV
• Rescheduling Cannabis: What Are The Implications For MSOs, Tax Rule 280E, FDA And Pharma?

  The potential of rescheduling and removing Tax Rule 280E could boost profits for U.S. businesses. However, Zuanic and Associates' latest report reveals complexities and overlooked consequences. What is the best option for unlocking the cannabis industry's potential: exploring exemptions or legislative change? Rescheduling MMJ: FDA And Pharma Implications Tax Rule 280E poses a considerable obstacle to cannabis companies, forcing them to pay income tax on gross profits and resulting in an astronomical effective tax rate of 70% for many US plant-touching businesses. While the removal of 280E through cannabis rescheduling appears attractive, Z&A cautions against embracing this narrative without considering its potential "Pandora's Box" of consequences. Rescheduling medical marijuana (MMJ) would indeed make it federally legal, but it could also usher in stricter FDA regulations and limit prescription accessibility for doctors. Additionally, it might lead to the entrance of pharmaceutical companies, altering the industry's dynamics significantly. “Moving MMJ to Schedule II or III would make MMJ federally legal with all that implies: FDA regulation, likely tougher for Drs to prescribe, ...Full story available on Benzinga.com

  Benzinga
• MSOs And Cannabis Rescheduling: A Safer Bet? Analyst Looks Closer At Pros And Cons

  Will the rescheduling of cannabis fuel a boom in cannabis stocks? Analysts from Z&A delve into the pros and cons of MSOs and cannabis rescheduling in their latest equity research report. Re-scheduling Vs. De-scheduling: What Is The Difference? Re-scheduling cannabis refers to the process of changing its current classification within the legal framework while maintaining some level of regulation. De-scheduling cannabis, on the other hand, involves removing it entirely from the list of controlled substances, eliminating all federal restrictions. If a country classifies cannabis as a Schedule I drug, re-scheduling it to Schedule II would mean acknowledging some medicinal value while retaining restrictions. De-scheduling would altogether remove all legal barriers, allowing it to be treated like any other non-controlled substance. Often, ...Full story available on Benzinga.com

  Benzinga
• 5 ETFs to Make the Most of Philip Morris's Q2 Earnings Beat

  Philip Morris beat both earnings and revenue estimates in the second quarter. Look into some ETFs to capitalize.

  Zacks Investment Research

  Featured Companies: FDL FSTA IYK PM XLP
• Altria: Time To Start Thinking About The End Of The Dividend

  The bad news for Altria never seems to end, with the FDA now proposing to ban JUUL E-cigarettes. Read what this could mean for MO stock.

  Seeking Alpha

  Featured Companies: DHS DIVZ FDL FORH MO WBIF WBIG XLP